PRRT in NET’s: Lu-177 PRRT and New Scope Alpha Treatment PRRT’nin NET’teki Yeri: Lu-177 PRRT ve Yeni Bakış Alfa tedavi

BİLGİÇ S., Demirci E., Selçuk N., KABASAKAL L.

Nuclear Medicine Seminars, vol.7, no.3, pp.300-309, 2021 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 7 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.4274/nts.galenos.2021.032
  • Journal Name: Nuclear Medicine Seminars
  • Journal Indexes: Scopus, EMBASE
  • Page Numbers: pp.300-309
  • Keywords: Ac-225, Ac-225DOTATATE, Lu-177-DOTATATE, Neuroendocrine tumor, Octreotide, PRRT, Theranostics
  • Bursa Uludag University Affiliated: No

Abstract

Somatostatin analogues labeled with peptide receptor radionuclide therapy (PRRT) have a long history in the treatment of neuroendocrine tumor (NET). Lu-177 DOTA TATE, whose efficacy has been proven by phase studies, is a treatment method that is easily tolerated by patients and has a low side-effect profile compared to alternative chemotherapeutics. After the success of Lu-177 DOTA TATE, alpha therapy (AT) was recommended to patients with clinically and histologically more aggressive tumors in order to increase the effectiveness of treatment via the same receptor. Pioneering publications on Ac-225 DOTA TATE therapy are promising for the future of therapy.